He discusses the data from the registrational trial that was presented at AAN last month, and the timeline of the BLA. Plus, myasthenia gravis, which is already in a pivotal, and other conditions the company is considering.

Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna's most advanced...

Peter Maag describes how Kyverna has been focused on this area for five years.